Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
The cash-strapped biotech has begun generating its first revenue from over-the-counter cosmetic treatments, as it pivots away from its original oncology drugs Key Takeaways: Kintor Pharma is shifting from its…
Recent Articles
RELATED ARTICLES
-
Plenty of room for growth in China’s hair transplant market
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- PegBio aims to bulk up its finances to deliver weight-loss drugs
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
